Mikulski, Stanislaw M <br/><br/>
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jan 2002 
 - 274-81 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2002.20.1.274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Mesothelioma--drug therapy<br/>Middle Aged<br/>Multivariate Analysis<br/>Proportional Hazards Models<br/>Ribonucleases--adverse effects<br/>Statistics, Nonparametric<br/>Survival Rate